Cited 0 times in Scipus Cited Count

Prognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis

DC Field Value Language
dc.contributor.authorPark, YJ-
dc.contributor.authorIm, Y-
dc.contributor.authorKwon, OJ-
dc.contributor.authorHan, J-
dc.contributor.authorAhn, MJ-
dc.contributor.authorKim, J-
dc.contributor.authorUm, SW-
dc.contributor.authorChoi, JY-
dc.date.accessioned2023-05-04T06:41:48Z-
dc.date.available2023-05-04T06:41:48Z-
dc.date.issued2023-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/25324-
dc.description.abstractPulmonary lymphangitic carcinomatosis (PLC) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). We sought to determine prognostic value of pretherapeutic fluorine-18-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in NSCLC with radiologically diagnosed PLC. We retrospectively reviewed 50 NSCLC patients with radiologically diagnosed PLC. Among eight clinical variables and five imaging parameters, metabolic PLC burden, which represents the overall tumor burden of PLC, and cPLC, which represents the location and extent of PLC in a three-grade system, were used. In multivariate analyses for progression-free survival, metabolic PLC burden (P = 0.0181), cPLC (P = 0.0401), and clinical stage (P = 0.0284) were identified as independent prognostic factors. High metabolic PLC burden had a worse prognosis, and the prognosis of cPLC3 was significantly worse than that of cPLC1 or cPLC2. In univariate analyses for overall survival, only age (P = 0.0073) was identified a prognostic factor. In conclusion, FDG PET/CT parameters were identified as independent prognostic factors in NSCLC with radiologically diagnosed PLC. Furthermore, a combination of anatomical and metabolic information about PLC obtained using FDG PET/CT provides insight into the overall tumor burden of PLC and is useful in predicting prognosis.-
dc.language.isoen-
dc.subject.MESHCarcinoma-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung-
dc.subject.MESHFluorodeoxyglucose F18-
dc.subject.MESHHumans-
dc.subject.MESHLung Neoplasms-
dc.subject.MESHNeoplasm Staging-
dc.subject.MESHPositron Emission Tomography Computed Tomography-
dc.subject.MESHPrognosis-
dc.subject.MESHRadiopharmaceuticals-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHTumor Burden-
dc.titlePrognostic value of pretherapeutic FDG PET/CT in non-small cell lung cancer with pulmonary lymphangitic carcinomatosis-
dc.typeArticle-
dc.identifier.pmid36611038-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9825376-
dc.contributor.affiliatedAuthorPark, YJ-
dc.type.localJournal Papers-
dc.identifier.doi10.1038/s41598-022-24875-2-
dc.citation.titleScientific reports-
dc.citation.volume13-
dc.citation.number1-
dc.citation.date2023-
dc.citation.startPage345-
dc.citation.endPage345-
dc.identifier.bibliographicCitationScientific reports, 13(1). : 345-345, 2023-
dc.identifier.eissn2045-2322-
dc.relation.journalidJ020452322-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Nuclear Medicine & Molecular Imaging
Files in This Item:
36611038.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse